Fri, Nov 22, 2024
Volume 16, Issue 3 (May-Jun 2022)
mljgoums 2022, 16(3): 14-18 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shalibeik S, Ghandehari F, Ahadi A, Rastegari A, Ghiasian M. Antibacterial Activity of the Peptide Microcin J25 Produced by Escherichia coli. mljgoums 2022; 16 (3) :14-18
URL: http://mlj.goums.ac.ir/article-1-1392-en.html
URL: http://mlj.goums.ac.ir/article-1-1392-en.html
Saman Shalibeik1 
, Fereshte Ghandehari 2, Ali-Mohammad Ahadi3 , Ali-Asghar Rastegari4 , Mojgan Ghiasian1
, Fereshte Ghandehari 2, Ali-Mohammad Ahadi3 , Ali-Asghar Rastegari4 , Mojgan Ghiasian1
1- Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
2- Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran ,saman000_sh@yahoo.com
3- Department of Genetics, Faculty of Science, Shahrekord University , Shahrekord, Iran
4- Department of Molecular and cell Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
2- Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran ,
3- Department of Genetics, Faculty of Science, Shahrekord University , Shahrekord, Iran
4- Department of Molecular and cell Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
Abstract: (1829 Views)
Background and objectives: Bacteriocins are generally active antimicrobial peptides effective against bacteria closely related to the producer. Escherichia coli produce two bacteriocins: colicins and microcins. Microcin J25 (Mcc J25) is an antibacterial peptide that inhibits bacterial transcription by disrupting the nucleotide-uptake channel of bacterial RNA polymerase. The objective of this study was to evaluate antimicrobial activity of MccJ25 produced by the bacteriocinogenic E. coli.
Methods: In this experimental study, 120 clinical specimens were selected from private diagnostic laboratories in Isfahan (Iran) in 2020. Antagonistic activity of isolates was tested by adopting agar plug method. Total DNA was extracted from clinical specimens and polymerase chain reaction (PCR) was performed using specific primers for amplification of the complete sequence of MccJ25 gene. Accuracy of the PCR products was confirmed by direct sequencing. Homology analysis was performed by using BLAST. Data were analyzed with Chromasv2.1.1 software.
Results: Overall, 120 E. coli strains were isolated from the clinical specimens. The antibiotic activity of Mcc J25 was mainly directed at Enterobacteriaceae, including several pathogenic E. coli strains of which 25 had positive well test samples, and about 5 (20%) of the collected clinical samples that were infected with E. coli had the MccJ25 gene.
Conclusions: Based on the results, Mcc J25 has favorable antibacterial potential, which can be further exploited as an alternative to chemical antibiotics.
Methods: In this experimental study, 120 clinical specimens were selected from private diagnostic laboratories in Isfahan (Iran) in 2020. Antagonistic activity of isolates was tested by adopting agar plug method. Total DNA was extracted from clinical specimens and polymerase chain reaction (PCR) was performed using specific primers for amplification of the complete sequence of MccJ25 gene. Accuracy of the PCR products was confirmed by direct sequencing. Homology analysis was performed by using BLAST. Data were analyzed with Chromasv2.1.1 software.
Results: Overall, 120 E. coli strains were isolated from the clinical specimens. The antibiotic activity of Mcc J25 was mainly directed at Enterobacteriaceae, including several pathogenic E. coli strains of which 25 had positive well test samples, and about 5 (20%) of the collected clinical samples that were infected with E. coli had the MccJ25 gene.
Conclusions: Based on the results, Mcc J25 has favorable antibacterial potential, which can be further exploited as an alternative to chemical antibiotics.
Research Article: Research Article |
Subject:
Microbiology
Received: 2021/06/17 | Accepted: 2021/08/22 | Published: 2022/05/14 | ePublished: 2022/05/14
Received: 2021/06/17 | Accepted: 2021/08/22 | Published: 2022/05/14 | ePublished: 2022/05/14
References
1. Juturu V, Wu JC. Microbial production of bacteriocins: Latest research development and applications. Biotechnology advances. 2018; 36(8): 2187-200. [View at Publisher] [DOI:10.1016/j.biotechadv.2018.10.007] [PubMed] [Google Scholar]
2. Rostami FM, Mousavi H, Mousavi MR, Shahsafi M. Efficacy of probiotics in prevention and treatment of infectious diseases. Clinical Microbiology Newsletter. 2018; 40(12): 97-103. [View at Publisher] [DOI:10.1016/j.clinmicnews.2018.06.001] [Google Scholar]
3. Zimina M, Babich O, Prosekov A, Sukhikh S, Ivanova S, Shevchenko M, et al. Overview of global trends in classification, methods of preparation and application of bacteriocins. Antibiotics. 2020; 9(9): 553. [View at Publisher] [DOI:10.3390/antibiotics9090553] [PubMed] [Google Scholar]
4. Martinez JL, Perez-Diaz JC. Isolation, characterization, and mode of action on Escherichia coli strains of microcin D93. Antimicrobial agents and chemotherapy. 1986; 29(3): 456-60. [View at Publisher] [DOI:10.1128/AAC.29.3.456] [PubMed] [Google Scholar]
5. Huang K, Zeng J, Liu X, Jiang T, Wang J. Structure of the mannose phosphotransferase system (man-PTS) complexed with microcin E492, a pore-forming bacteriocin. Cell discovery. 2021; 7(1): 1-5. [View at Publisher] [DOI:10.1038/s41421-021-00253-6] [PubMed] [Google Scholar]
6. Collin F, Maxwell A. The microbial toxin microcin B17: prospects for the development of new antibacterial agents. Journal of molecular biology. 2019 Aug 23;431(18):3400-26. [View at Publisher] [DOI:10.1016/j.jmb.2019.05.050] [PubMed] [Google Scholar]
7. Martin-Gómez H, Tulla-Puche J. Lasso peptides: chemical approaches and structural elucidation. Organic & biomolecular chemistry. 2018; 16(28): 5065-80. [View at Publisher] [DOI:10.1039/C8OB01304G] [PubMed] [Google Scholar]
8. Rebuffat SF, Telhig S, Said LB, Zirah S, Ismail F. Bacteriocins to thwart bacterial resistance in Gram-negative bacteria. Frontiers in microbiology. 2020;11:2807. [View at Publisher] [DOI:10.3389/fmicb.2020.586433] [PubMed] [Google Scholar]
9. Naimi S, Zirah S, Hammami R, Fernandez B, Rebuffat S, Fliss I. Fate and biological activity of the antimicrobial lasso peptide microcin J25 under gastrointestinal tract conditions. Frontiers in microbiology. 2018; 9: 1764. [View at Publisher] [DOI:10.3389/fmicb.2018.01764] [PubMed] [Google Scholar]
10. Koltan M, Corbalan NS, Molina VM, Elisei A, de Titto GA, Eisenberg P, et al. Anti-E. coli cellulose-based materials. LWT. 2019; 107: 325-30. [View at Publisher] [DOI:10.1016/j.lwt.2019.02.084] [Google Scholar]
11. El-Kholy M, El-Shinawy S, Meshref A, Korny A. Screening of Antagonistic Activity of Probiotic Bacteria Against Some Food-Borne Pathogens. Journal of Food Biosciences and Technology. JFBT. 2014; 4(2): 1-14. [View at Publisher] [Google Scholar]
12. Ayeni FA, Adeniyi BA, Ogunbanwo ST, Tabasco R, Paarup T, Peláez C, Requena T. Inhibition of uropathogens by lactic acid bacteria isolated from dairy foods and cow's intestine in western Nigeria. Archives of microbiology. 2009 Aug;191(8):639-48. [View at Publisher] [DOI:10.1007/s00203-009-0492-9] [PubMed] [Google Scholar]
13. Gradisteanu Pircalabioru G, Popa LI, Marutescu L, Gheorghe I, Popa M, Czobor Barbu I, et al. Bacteriocins in the Era of antibiotic resistance: rising to the challenge. Pharmaceutics. 2021; 13(2): 196. [View at Publisher] [DOI:10.3390/pharmaceutics13020196] [PubMed] [Google Scholar]
14. Sassone-Corsi M, Nuccio SP, Liu H, Hernandez D, Vu CT, Takahashi AA, et al. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature. 2016; 540(7632): 280-3. [View at Publisher] [DOI:10.1038/nature20557] [PubMed] [Google Scholar]
15. Nasresfahani M, Ahadi A M, Ayat H, Nayeri H. Evaluation of E492 Microcin Gene Presence in Klebsiella pneumoniae Collected from Patients Registered to Educational Hospitals of Isfahan. Zahedan J Res Med Sci. 2017; 19(1): e5038. [View at Publisher] [DOI:10.17795/zjrms-5038] [Google Scholar]
16. Sable S, Pons AM, Gendron-Gaillard S, Cottenceau G. Antibacterial activity evaluation of microcin J25 against diarrheagenic Escherichia coli. Applied and environmental microbiology. 2000; 66(10): 4595-7. [View at Publisher] [DOI:10.1128/AEM.66.10.4595-4597.2000] [PubMed] [Google Scholar]
17. Budič M, Rijavec M, Petkovšek Ž, Žgur-Bertok D. Escherichia coli bacteriocins: antimicrobial efficacy and prevalence among isolates from patients with bacteraemia. PLoS One. 2011; 6(12): e28769. [View at Publisher] [DOI:10.1371/journal.pone.0028769] [PubMed] [Google Scholar]
18. Jeziorowski A, Gordon DM. Evolution of microcin V and colicin Ia plasmids in Escherichia coli. Journal of bacteriology. 2007; 189(19): 7045-52. [View at Publisher] [DOI:10.1128/JB.00243-07] [PubMed] [Google Scholar]
19. Hyati M, Kargar M, Pourbakhsh A, Shirazi Z, Tahamtan Y, Namvari M, et al. Detection of Colicin genes by PCR in Escherichia coli isolated from cattle in Shiraz-Iran. Archives of Razi Institute. 2012; 67(1): 63-67. [View at Publisher] [DOI] [Google Scholar]
20. Micenková L, Štaudová B, Bosák J, Mikalová L, Littnerová S, Vrba M, Ševčíková A, Woznicová V, Šmajs D. Bacteriocin-encoding genes and ExPEC virulence determinants are associated in human fecal Escherichia coli strains. BMC microbiology. 2014; 14(1): 1-9. [View at Publisher] [DOI:10.1186/1471-2180-14-109] [PubMed] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.